KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis
Marc Peeters(University of Antwerp), Scott D. Patterson(Gilead Sciences (United States)), Yevhen Hotko(Ghent University Hospital), Cornelis J.A. Punt(Utrecht University), Kelly S. Oliner(Amgen (United States)), Florian Lordick(Leipzig University), G. Wilson(Ghent University Hospital), Timothy Price(Basil Hetzel Institute), Laslo Roman(Ghent University Hospital), Thierry André(Inserm), Michel Ducreux(Université Paris-Saclay), Emily Chan(Royal Marsden NHS Foundation Trust), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Alberto F. Sobrero(Ospedale Policlinico San Martino), Andrés Cervantes(INCLIVA Health Research Institute), Hua Yu(Amgen (United States)), A. H. Strickland(Monash Medical Centre), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), R. Sidhu(Amgen (United States)), A. Scott Jung(Amgen (United States))
Cited by 3
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k